Behind the Study
Scientific Team & Facilities
The EIMEC study was conducted by an independent team of researchers at their Barcelona facilities — no affiliation with CREGEN or KAIST.
The European Institute of Medical and Exercise Cognition ran an independent controlled pilot study on CREGEN — with no stake in the outcome. Early results point to better creatine retention and bioavailability than market competitors.
EIMEC did not create CREGEN. They did not fund CREGEN. They are not affiliated with CREGEN or with KAIST. Their only job was to verify whether the science held up — with their own cohort, their own protocol, their own methodology.
That is what makes the result meaningful. KAIST invented the CGG Amino-Bridge™. EIMEC, an independent EU institution in Barcelona, set out to challenge it. The data matched.
EIMEC tracked creatine across serum, plasma, and urinary markers. The standout result: significantly lower urinary creatine loss versus a competitor — with consistent directional trends toward higher serum and plasma levels. Preliminary data from a small controlled cohort.
CREGEN vs Competitor 1 — Creatine Markers
Mean values per marker (n=2 per group · 5 g/day · 15 days). Bars are scaled within each marker pair so the comparison is visible across very different units; exact values are labelled on every bar.
* p<0.05 (statistically significant). Urine-spot creatine was ~56% lower with CREGEN (833.3 vs 1900.0) — less creatine flushed out, better retention. Serum and plasma trended higher (more in circulation) but did not reach significance at this pilot's small sample. Pilot study — preliminary and exploratory; larger studies are needed to confirm.
The EIMEC study was conducted by an independent team of researchers at their Barcelona facilities — no affiliation with CREGEN or KAIST.
EIMEC designed its own independent methodology. No shared protocol with KAIST. No access to the original study design. A clean, independent verification.
Different countries. Different populations. Different methodologies. Same conclusion. That is the standard CREGEN holds its science to.
EIMEC measured bioavailability — how much of the creatine in CREGEN actually enters and stays in the bloodstream versus being excreted. They tracked creatine across serum, plasma, clearance, and urinary excretion. The standout result was significantly lower urinary creatine loss versus a competitor (p<0.05), with directional trends toward higher serum and plasma creatine. As a pilot study, the results are preliminary.
KAIST — the Korea Advanced Institute of Science and Technology — is where the CGG Amino-Bridge™ technology was discovered and developed. EIMEC, an independent European institute in Barcelona, ran its own study on a completely separate European population to verify those findings from the outside. One created the science; the other checked it with no conflict of interest.
The pilot tracked how much creatine is absorbed and retained versus excreted. CREGEN showed significantly lower urinary creatine loss (p<0.05) and higher serum and plasma levels than a competitor — pointing toward greater systemic bioavailability driven by the CGG Amino-Bridge™ delivery system. Because the sample was small, these are preliminary findings that larger studies are designed to confirm.
Yes. Full study summaries — covering methodology, cohort demographics, and the complete dataset — are available on request to verified retail partners, healthcare practitioners, and serious customers. Email info@cregenusa.com with your details and we will send access within 2 business days.
A single study — however rigorous — is one data point. Independent replication by a separate institution, with a different cohort and methodology, is the standard by which science earns trust. EIMEC's corroboration of the KAIST findings means the result was not a statistical outlier, not a Korean-population-specific effect, and not influenced by any shared institutional interest. That is what "validated" means in a scientific context.
An independent pilot pointing in a promising direction (preliminary). Try CREGEN for 30 days — or get a full refund. No questions asked.
